MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Key Takeaways MLTX surged 18% on a report that Merck submitted a non-binding buyout offer earlier this year. The rumored deal would value MoonLake at over $3 billion, though the initial offer was reportedly rejected. Merck's interest may reflect a strategy to diversify beyond Keytruda by adding novel drug candidatesShares of small-biotech MoonLake Immunotherapeutics (MLTX) rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck (MRK) is interested in ...